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Background. Liver diseases are the leading causes of death in human immunodeﬁciency virus (HIV)–positive
persons since the widespread use of combination antiretroviral treatment (cART). Most of these deaths are due to
hepatitis C (HCV) or B (HBV) virus coinfections. Little is known about other causes. Prolonged exposure to some
antiretroviral drugs might increase hepatic mortality.
Methods. All patients in the Data Collection on Adverse Events of Anti-HIV Drugs study without HCV or
HBV coinfection were prospectively followed from date of entry until death or last follow-up. In patients with
liver-related death, clinical charts were reviewed using a structured questionnaire.
Results. We followed 22 910 participants without hepatitis virus coinfection for 114 478 person-years. There
were 12 liver-related deaths (incidence, 0.10/1000 person-years); 7 due to severe alcohol use and 5 due to estab-
lished ART-related toxicity. The rate of ART-related deaths in treatment-experienced persons was 0.04/1000
person-years (95% conﬁdence interval, .01, .10).
Conclusions. We found a low incidence of liver-related deaths in HIV-infected persons without HCV or HBV
coinfection. Liver-related mortality because of ART-related toxicity was rare.
Keywords. liver-related mortality; drug toxicity; antiretroviral therapy; HIV infection; cohort study.
Liver diseases are among the most frequent causes of
non-AIDS–related deaths in human immunodeﬁcien-
cy virus (HIV)-positive persons [1–4]. Most deaths
result from hepatitis C (HCV) or hepatitis B virus
(HBV) coinfections or alcohol use; little is known
about other causes [5]. Results of 2 prospective obser-
vational cohorts suggest that prolonged exposure to
antiretroviral therapy (ART) may increase the risk for
fatal liver failure. The Data Collection on Adverse
Events of Anti-HIV Drug (D:A:D) cohort, which in-
cludes many HCV-coinfected persons, found an in-
creased rate of liver-related deaths per year of ART in
multivariable analyses that were also adjusted for the
latest CD4 cell counts [1]. The EuroSIDA observation-
al cohort showed similar results [6].
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The role of ART in liver-related mortality in patients without
chronic viral hepatitis is less well deﬁned. In the Swiss HIV
Cohort Study (SHCS), elevated alanin aminotransferase (ALT;
reported as adverse events to antiretrovirals), was associated
with a higher mortality, independent of chronic hepatitis virus
coinfections [7]. In contrast, mortality was not increased in par-
ticipants with chronic ALT elevation and without viral hepatitis
in another SHCS analysis; however, the observation period was
shorter and the patient number smaller [8]. Recently, new hepa-
tic syndromes related to ART have emerged in HIV-infected
persons. Noncirrhotic portal hypertension, a potentially life-
threatening liver disease, has been linked to didanosine use [9, 10].
In addition, steatosis and steatohepatitis are common in
HIV-positive persons with and without chronic viral hepatitis
[11, 12] and are associated with advanced liver ﬁbrosis and
cirrhosis [13]; ART as a risk factor has been discussed.
The aims of this study were to (1) assess liver-related mor-
tality in HIV-positive persons without chronic viral hepatitis
in the D:A:D cohort and (2) provide comprehensive clinical
details of these events. The role of ART in death was of partic-
ular interest.
METHODS
Study Design
The D:A:D study, which was founded in 1999, is a prospective
observational study of 11 previously established cohorts, as de-
scribed previously [14]. Currently, 49 737 HIV-positive indi-
viduals (33 308 from the original 2 recruitments with 16 429
added to the cohort from 2009) are followed at 212 clinics in
Europe, the United States, and Australia. The study’s primary
endpoint is myocardial infarction, with other events (includ-
ing death) as secondary endpoints.
Data Collection
All participants were under active follow-up in their individual
cohorts at the time of enrollment in the D:A:D study. At enroll-
ment and at least every 8 months thereafter, standardized data
forms, which are used to collect information on socio-
demographic, clinical, laboratory, and treatment information,
are completed. Data on HBV and HCV antibody status and
hepatitis viral load assessments, if available, have been collected
since January 2004. Previously collected HBV or HCV results
by the participating cohorts were included. Information on
cause of death has been prospectively collected using the Cause
of Death (CoDe) in HIV protocol, which is speciﬁcally designed
for classifying causes of death in HIV-positive persons [15].
For the present analysis, deaths were classiﬁed as liver related
if the underlying cause was recorded as liver failure, regardless
of etiology. Other categories include AIDS, cardiovascular
disease (CVD), non-AIDS malignancy (excluding AIDS-
deﬁning and hepatitis virus-associated malignancies), and
other/unknown.
In all persons with liver-related death and negative HCV or
HBV status, local investigators of participating institutions ret-
rospectively reviewed the clinical charts using a structured
questionnaire. This chart review ascertained that inclusion cri-
teria were met and provided additional information on the
cause of liver-related death (including severe alcohol use, non-
alcoholic fatty liver disease, medical treatment, noncirrhotic
portal hypertension, and other disorders), liver-related symp-
toms, laboratory and histology results, and interventions, in-
cluding liver transplantation. In unclear circumstances of
liver-related death, a brief narrative was given.
Deﬁnitions
HCV infection was deﬁned as present in persons who were
seropositive for HCV or who had test results positive for HCV
RNA. HBV infection was deﬁned as present in persons who
were positive for hepatitis B surface antigen, hepatitis B e
antigen, or hepatitis B core antibodies or who had detectable
HBV DNA during the study period. Thus, patients with
chronic and previous HCV infections and chronic, active, and
previous HBV infections were excluded. Patients with
unknown HBV or HCV status were also excluded. Severe
alcohol use was deﬁned according to the WHO deﬁnition as
alcohol consumption in female >40 g/d and in male >60 g/d.
Statistical Analyses
All D:A:D study participants with negative HCV and HBV
status were included. Participants were followed from the date
of entry into the D:A:D study until the date of death, the date
of loss to follow-up (6 months after the patient’s last clinic
visit), or the end of study follow-up (1 February 2010), which-
ever occurred ﬁrst. The incidence of liver-related deaths was
deﬁned as the number of such deaths divided by the total
person-years of follow-up. HCV- or HBV-negative partici-
pants with liver-related death were compared with participants
without chronic viral hepatitis who died from causes that were
not liver related using data at baseline and data from the last
clinic visit before death. P values were calculated using Fisher
exact tests and Mann-Whitney U tests, as appropriate. Due to
the small number of endpoints, multivariable analyses were
not feasible. Analyses were performed using SAS version 9.1.
RESULTS
Baseline Characteristics
Of 49 737 participants followed between 1 December 1999
and 1 February 2010, 19 618 (40%) were HCV or HBV posi-
tive at baseline or during follow-up and 2506 (5%) had
unknown HCV or HBV status. A total of 4703 (9%)
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participants were excluded because they belonged to cohorts
that did not provide the requested information for this study.
Thus, 22 910 (46%) HCV- and HBV-negative participants
who were followed for 114 478 patient-years were included in
these analyses (Figure 1). Over the years, the percentage of pa-
tients with documentation gaps of more than 1 year remained
low and varied between 3% and 6%. The baseline characteris-
tics of the study participants are shown in Table 1.
A total of 1059 (4.6%) of the patients died; 12 (0.05%)
deaths were liver related. Thus, the incidence of liver-related
deaths in persons not coinfected with HCV or HBV was 0.10/
1000 person-years (95% conﬁdence interval [CI], .05, .18).
Description of Patients Who Died From Liver Disease
Clinical data are summarized in Table 2. Five participants
died due to ART toxicity. Of these, 2 patients experienced
acute liver failure with lactic acidosis on regimens that includ-
ed didanosine and stavudine, with 1 patient also receiving
metformin. A third patient developed fatal liver failure
because of a hypersensitivity reaction to nevirapine. Two pa-
tients died of noncirrhotic portal hypertension; both had been
exposed to didanosine. The rate of ART-related death in treat-
ment-experienced individuals was 0.04 (95% CI, 0.01, 0.10),
with 5 events over 1000 person-years. Seven liver-related
deaths were due to severe alcohol use, including 1 patient with
an additional diagnosis of hemochromatosis.
Histopathological ﬁndings (2 biopsies and 1 autopsy) con-
ﬁrmed the clinical diagnosis of alcoholic liver disease and
noncirrhotic portal hypertension. (Signs of alcoholic liver
disease were found in 1 biopsy and in the autopsy of 2 pa-
tients with alcoholic liver disease, and 1 biopsy of a patient
with noncirrhotic portal hypertension showed histopathologi-
cal ﬁndings consistent with noncirrhotic portal hypertension)
[10, 16]. No patient was treated with transjugular intrahe-
patic portal systemic shunting and none received a liver
transplant.
Figure 1. Patient ﬂowchart. Abbreviations: D:A:D, Data Collection on Adverse Events of Anti-HIV Drug; HBV, hepatitis B virus; HCV, hepatitis C virus.
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Comparison of Patients Who Died From Liver-Related Death
With Patients Who Did Not Die From Liver-Related Death
Participants who died from all causes compared with patients
who remained alive were more often male and were older.
Their ﬁrst HIV diagnosis was earlier, their nadir and baseline
CD4 cell counts were lower, maximum HIV-1 RNA levels
were higher, and a history of previous clinical AIDS was more
frequent (data not shown).
Patients who died from liver-related causes compared with
patients who died from other causes (AIDS 376 [35.9%], CVD
116 [11.1%], non-AIDS malignancies 149 [14.2%], other
causes 315 [30.1%], unknown causes 91 [8.7%]) were exposed
to ART at baseline for a signiﬁcantly longer period of time.
Time of ﬁrst HIV diagnosis was earlier and enrollment in the
D:A:D study was earlier, probably reﬂecting longer duration of
HIV infection (Table 3).
DISCUSSION
In this large prospective cohort of 22 910 HIV-positive partici-
pants without hepatitis coinfection who were followed for
114 478 patient-years, the incidence of liver-related deaths was
very low at 0.10/1000 patient-years. Among the 12 persons
who died from liver-related causes, 7 died because of alcohol
use and 5 most probably as a consequence of ART-related
hepatotoxicity.
In the large population-based National Health and Nutri-
tion Examination Survey (NHANES) III study in the United
States, liver-related mortality in adults who were HCV anti-
body negative was 0.16 (95% CI, .10–.25) per 1000 person-
years; this is very similar to our ﬁnding of 0.10 (0.05–0.18) per
1000 person-years among HIV-positive individuals without
HCV or HBV. However, in the NHANES III study, mortality
of persons with chronic HCV infection was 4.4 (1.5–12.9) per
1000 person-years [17].
In HIV-positive persons without HCV or HBV coinfection,
limited data are available on liver-related mortality. In the
French Mortavic study, 48 of 287 deaths (17%) in HIV-posi-
tive individuals in 2005 were related to end-stage liver disease,
of which 94% of deaths were attributable to chronic viral hep-
atitis. Severe alcohol use was reported in nearly half of the pa-
tients, and only 3 of 48 persons were HCV/HBV-negative [3].
In a recent collaborative analysis of 13 HIV cohorts, 113 of
1876 deaths (7%) were related to liver diseases. In 50 patients
(44%), hepatitis viruses were not the cause of liver-related
death. However, information on the proportion of patients
with positive or unknown HCV/HBV serostatus was missing
[18]. A previous analysis of the D:A:D study group found 341
of 2482 deaths (14%) to be liver related; 56 patients (2.3%)
with liver failure had no documentation of chronic viral hepa-
titis [4]. However, our current reinvestigation showed that
chronic hepatitis virus infection was frequent in the group
without HCV or HBV documentation.
We found that noncirrhotic portal hypertension was the
cause of only 2 liver-related deaths. Several case series and
case reports on the disease have been published recently [10,
Table 1. Characteristics of Data Collection on Adverse Events
of Anti-HIV Drug Study Participants Without Hepatitis C Virus or
Hepatitis B Virus Coinfection at Study Entry
Total of Participants n 22 910
Male gender n (%) 16 737 (73.1)
Age (y) Median (IQR) 38 (32, 46)
Period of D:A:D cohort
registration, n (%)
≤2002 11 896 (51.9)
2003–2006 7060 (30.8)
2007–2009 3954 (17.3)
Duration of D:A:D cohort
follow-up
Median (IQR) 4.9 (2.2, 8.3)
Ethnicity, n (%) White 10 827 (47.3)
Black 1762 (7.7)
Other 499 (2.2)
Unknown 9817 (42.9)
Mode of HIV transmission,
n (%)
Heterosexual 9472 (41.3)
Homosexual 11 430 (49.9)
IDU 404 (1.8)
Other/
unknown
1604 (7.0)
Year of first HIV diagnosis Median (IQR) 1999 (1994, 2004)
BMI (kg/m2), n (%) <18 621 (2.7)
≥18, ≤26 13 228 (57.7)
>26, ≤30 2618 (11.4)
>30 902 (3.9)
Unknown 5541 (24.2)
Diabetes mellitus n (%) 597 (2.6)
Smoking status, n (%) Current 7014 (30.6)
Former 4715 (20.6)
Never 6788 (29.6)
Unknown 4393 (19.2)
CD4 cells/µL Median (IQR) 410 (250, 595)
n (%) <200 3837 (17.9)
Previous clinical AIDS n (%) 5176 (22.6)
Cumulative ART exposure (y) Median (IQR) 0.9 (0.0, 3.5)
Cumulative NRTI exposure (y) Median (IQR) 0.8 (0.0, 3.5)
Cumulative PI exposure (y) Median (IQR) 0.0 (0.0, 2.1)
Cumulative NNRTI exposure (y) Median (IQR) 0.0 (0.0, 0.3)
Treatment status, n (%) Naïve 8724 (38.1)
Interruption 1072 (4.7)
on ART 13 114 (57.2)
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; D:A:D, Data
Collection on Adverse Events of Anti-HIV Drug; HIV, human
immunodeficiency virus; IDU, intravenous drug use; IQR, interquartile range;
NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside
reverse transcriptase inhibitor; PI, protease inhibitor.
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Table 2. Clinical Description of Human Immunodeﬁciency Virus–Positive Patients Without Hepatitis C Virus or Hepatitis B Virus Infection and Liver-Related Death
Patient
Cause of
Death
Date of
Death
Clinical
Manifestations Sex
Age
at BL
First HIV
Diagnosis
CD4 Cell
Count/μL HIV RNAa
CDC Stage C
Exposure
to ART (y)
Comments
BL Last BL Last BL Last
1 Alcohol 2003 Esophageal varices, ascites M 55 1984 420 350 <50 5.37 yes 5.7 7.4
2 Alcohol 2005 Not reported M 38 1988 322 137 <50 4.08 yes 6.9 11.9
3 Alcohol 2005 Splenomegaly M 34 1991 174 236 3.45 <50 yes 6.3 11.7 Hemochromatosis
4 Alcohol 2001 Ascites, encephalopathy, HCC M 57 1991 640 350 <50 <50 yes 3.8 4.3
5 Alcohol 2003 Not reported M 40 1986 297 242 4.20 5.00 no 8.5 10.9
6 Alcohol 2007 Splenomegaly, ascites M 35 1995 375 311 3.40 4.11 no 4.4 8.6
7 Alcohol 2004 Splenomegaly, esophageal
varices, varicel bleeding, ascites
F 34 2000 405 247 4.18 5.62 no 0 0
8 NCPH 2000 Splenomegaly, esophageal varices,
ascites
M 56 1990 114 114 <50 1.70 no 8.0 8.4 NCPH, ddI
9 ART 2001 Splenomegaly, encephalopathy M 82 1994 437 437 1.94 1.99 no 5.6 6.1 Lactic acidosis: ddI, d4T
10 ART 2000 Ascites F 46 1993 1080 1080 <50 <50 yes 3.4 3.5 Hypersens: NVP
11 ART 2006 Splenomegaly, esophageal varices,
ascites, encephalopathy
M 44 1996 309 327 3.73 4.66 yes 5.4 9.1 Lactic acidosis: ddl,
D4T, metformin
12 NCPH 2001 Splenomegaly, esophageal varices,
portal vein thrombosis
M 54 1993 175 339 3.63 3.48 no 5.5 6.6 NCPH, ddI
Abbreviations: ART, antiretroviral therapy; BL, baseline; ddI, didanosine; D4T, stavudine; EFV, efavirenz; F, female; HCC, hepatocellular carcinoma; hypersens, hypersensitivity reaction; M, male; NCPH, noncirrhotic
portal hypertension; NVP, nevirapine.
aLog10 copies/mL or below 50 HIV RNA copies/mL.
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16, 19–22]. The pathogenesis was found to be multifactorial,
with didanosine exposure as an important risk factor. Patients
present with esophageal varices, ascites, splenomegaly, portal
vein thrombosis, variceal hemorrhage, or liver failure as severe
and life-threatening complications. Mortality in advanced
stages of disease is high [10]. Fortunately, current data indicate
that it is indeed a rare disease with a lower mortality than pre-
viously suspected.
We found 2 liver-related deaths attributable to severe hyper-
lactataemia. In both cases, regimens included stavudine and
Table 3. Comparison of Characteristics of Hepatitis C Virus (HCV)– and Hepatitis B Virus (HBV)–Seronegative Patients With Liver-
related Death With HCV- and HBV-seronegative Patients Dying From Other Causes
Characteristic Liver-Related Death Death From Other Causesa P Value
No. of patients (%) 12 (100) 1047 (100)
Male gender,
n (%) 10 (83.3) 876 (83.7) 1.00
Age (y)
Median (IQR) 45 (36, 55) 47 (38, 57) .74
Year of first HIV diagnosis
Median (IQR) 92 (89, 94) 95 (90, 00) .05
Date of D:A:D cohort registration
≤2002 12 (100.0) 793 (75.7) .15
2003–2006 0 216 (20.6)
2007–2009 0 38 (3.6)
At baseline
Exposure to ART, y
Median (IQR) 5.5 (4.1, 6.6) 2.8 (0.1, 5.2) .008
Treatment status, n(%)
Naive 1 (8.3) 238 (22.7) .23
Interruption 0 (-) 84 (8.0)
On ART 11 (91.7) 725 (69.3)
At last visit
Nadir CD4 cells/µL
Median (IQR) 97 (56, 171) 70 (16, 165) .50
Peak HIV-1 RNA (log10 copies/mL)
Median (IQR) 5.2 (4.9, 5.6) 5.3 (4.7, 5.8) .45
Previous clinical AIDS,
n (%) 6 (50.0) 688 (65.7) .40
Cumulative ART exposure
Any, y
Median (IQR) 7.9 (5.2, 10.0) 5.6 (1.5, 8.9) .14
NRTIs, y
Median (IQR) 7.9 (5.2, 10.0) 5.4 (1.5, 8.6) .11
NNRTIs, y
Median (IQR) 0.9 (0.0, 1.6) 0.6 (0.0, 2.2) .98
PIs, y
Median (IQR) 3.5 (0.2, 6.8) 2.7 (0.3, 5.1) .68
Current treatment status, n (%)
Naive 1 (8.3) 66 (6.3) .75
Interruption 3 (25.0) 370 (35.3)
On ART 8 (66.7) 611 (58.4)
Abbreviations: ART, antiretroviral therapy; D:A:D, Data Collection on Adverse Events of Anti-HIV Drug; HIV, hummunodecifiency virus; IQR, interquartile range;
NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
a Death from other causes, n (%): AIDS, 376 (35.9); cardiovascular disease, 116 (11.1); non-AIDS malignancies, 149 (14.2); other causes, 315 (30.1); unknown
causes, 91 (8.7).
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didanosine. Exposure to nucleoside reverse transcriptase in-
hibitors, particularly to the dideoxynucleosides (didanosine,
stavudine, and zalcitabine), is associated with the inhibition of
mitochondrial DNA γ-polymerase, leading to severe hyperlac-
tatemia. Lactic acidosis is rarely observed; however, the mor-
tality rate is high [23, 24], which is the reason that these drugs
are no longer recommended. Nonnucleoside reverse transcrip-
tase inhibitors, especially nevirapine, are associated with an in-
creased risk of acute hepatotoxicity, typically due to
hypersensitivity reactions. In line with our study ﬁndings,
such adverse events are rare [25, 26].
We expected that liver-related deaths in persons not coin-
fected with hepatitis viruses were frequently due to severe
alcohol consumption. Among HIV-positive persons, the re-
ported prevalence of severe alcohol use ranges from 2.8% to
35%, depending on the observed population [27–30].
However, we found a low rate of death to be due to alcoholic
liver disease, which is probably explained by the exclusion of
many at-risk patients such as injection-drug users. Those in
this patient group, who are at risk for multiple substance-de-
pendence syndromes including alcohol [30], were almost
completely excluded from analyses because of chronic viral
hepatitis.
In agreement with other investigations, older age, male
gender, lower CD4 cell counts, high HIV-1 viral load, and pre-
vious clinical AIDS were associated with death from all causes
[18, 31]. We found that patients with liver-related death had
been exposed to ART for a longer period of time and were
known to be HIV-infected for a longer period of time. Both of
these conditions might indicate a longer exposure to older and
more hepatotoxic antiretrovirals. This is also true for patients
with alcoholic liver disease, in whom the cause of death might
have been multifactorial. However, this remains speculative
because of the low number of endpoints.
The strength of this study is its large size and the long-term
prospective observation. Additionally, the endpoint, that is,
liver-related cause of death, was prospectively collected and
centrally adjudicated using the CoDe system. Limitations are
that multivariable analyses to identify associated risk factors
were not possible because of the rare occurrence of endpoints
under investigation; information on severe alcohol use was
available only in case patients; and liver-related deaths were
retrospectively reevaluated. We cannot rule out some under-
reporting of liver-related deaths. First, liver-related deaths
might be difﬁcult to capture because of multiple potential con-
tributing factors (eg, sepsis or renal dysfunction). Central ad-
judication by several experienced clinicians, however, should
have minimized such misclassiﬁcations. Second, some patients
may have experienced liver-related death after being lost to
follow-up, a scenario that might be more common in patients
with alcoholic liver disease. However, because patients totally
lost from HIV care are unlikely to be on ART, these missed
events are unlikely to contribute to rates of ART-related liver
mortality. Furthermore, because follow-up on such patients is
right-censored on the date of loss to follow-up, our rate esti-
mates should not be substantially biased by the exclusion of
these events. Finally, given the very small number of events
that limited a multivariable analysis of predictors of these
liver-related deaths, it was not possible to perform a formal
competing risks analysis to account for individuals who died
of other causes prior to the clinical manifestation of liver
disease.
In conclusion, this is the ﬁrst large study to assess liver-
related deaths in HCV or HBV seronegative patients. The inci-
dence of liver-related deaths unrelated to chronic viral hepati-
tis, in particular life-threatening hepatotoxic side effects due
to antiretrovirals, was very low and comparable to that of the
general HCV-negative population in the United States. This is
good news in times when HIV infection has evolved into a
chronic disease, lifelong ART remains a necessity, earlier
therapy for all HIV-positive persons is a matter of debate, and
more comedication—potentially leading to drug–drug interac-
tions and hepatotoxicity—will be necessary in this aging and
multimorbid population. Therefore, ongoing monitoring of
liver-related mortality and its contributors in HIV-positive
persons will remain important.
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